A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

This study is looking for adults aged 18 or over. You would need to have been diagnosed with rheumatoid arthritis using specific criteria, and your RA should still be active with a certain number of tender and swollen joints, and markers in your blood.

Crucially, your RA must have proven difficult to treat, meaning that at least two previous types of powerful RA medications haven't worked well enough for you. You also need to have a specific type of antibody in your blood called ACPA.

There are also some reasons why you might not be able to join. For example, if you've recently had certain other treatments, have other specific inflammatory joint conditions, a history of certain cancers, or problems with your immune system, this study might not be right for you. Your doctor will check all these details carefully.

If you join this study, it could last up to 86 weeks, which is about a year and a half. For the first 16 weeks, everyone will receive the study medicine openly. After that, for 12 weeks, you'll be randomly given either the study medicine or a placebo (a dummy treatment), and you won't know which one you're getting. There's also an optional additional period of up to 48 weeks where you might continue receiving the study medicine.

Throughout the study, you'll have regular visits to the clinic for check-ups. These visits will involve various assessments, including checking your joints, blood tests, and discussing your symptoms and how you're feeling. The team will explain exactly what's involved at each visit and answer any questions you have.